2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

Fraenkel, Liana; Bathon, Joan M.; England, Bryant R.; Clair, E. William St.; Arayssi, Thurayya; Carandang, Kristine; Deane, Kevin D.; Genovese, Mark C.; Huston, K.; Kerr, Gail S.; Kremer, Joel M.; Nakamura, Mary C.; Russell, Linda; Singh, Jasvinder A; Smith, Benjamin J.; Sparks, Jeffrey A.; Venkatachalam, Shilpa; Weinblatt, Michael E.; Al-Gibbawi, Mounir; Baker, Joshua F.; Barbour, Kamil E.; Barton, Jennifer L.; Cappelli, Laura C.; Chamseddine, Fatimah; George, Michael; Johnson, Sindhu R.; Kahale, Lara A; Karam, Basil S.; Khamis, Assem M.; Navarro‐Millán, Iris; Mirza, Reza; Schwab, Pascale; Singh, Namrata; Turgunbaev, Marat; Turner, Amy S.; Yaacoub, Sally; Akl, Elie A.

doi:10.1002/acr.24596

Cited by 551 publications

(359 citation statements)

References 70 publications

Supporting

Mentioning

340

Contrasting

Unclassified

Order By: Relevance

“…Given that a biosimilar has no clinically meaningful differences from the originator in terms of safety, purity, and potency, such a decision to switch to a biosimilar after treatment failure on the reference biologic would also be expected to have undesirable outcomes. In fact, evidence-based guidelines on medical switching of biologics for multiple conditions, including RA and IBD, recommend switching patients who experience inadequate response or an adverse event with a biologic to an entirely different class of biologic or treatment option [21,22]. Taken together, these findings indicated significant educational needs to address knowledge gaps associated with biosimilars.…”

Section: Do Increases In Uptake Mirror Gains In Education?mentioning

confidence: 99%

Biosimilar Uptake: The Importance of Healthcare Provider Education

Oskouei

Kusmierczyk

2021

Pharm Med

View full text Add to dashboard Cite

From peptide hormones to monoclonal antibodies, advances in biotherapeutic medicines, or biologics, have brought incalculable benefits to patients, especially for conditions where previous classes of therapy were ineffective or non-existent. At the same time, the development of biologics has been accompanied by questions of access and cost. The advent of biosimilars, molecules highly similar to their reference biologics, has offered the promise of ameliorating cost and access challenges. However, issues regarding biosimilar uptake remain. Multiple factors impact the utilization of biosimilars by healthcare providers and perhaps the best recognized of these is education. This paper discusses the importance of education to biosimilar adoption and lists action-items that various stakeholders in healthcare can adopt to improve the overall understanding of this important class of therapeutics.

show abstract

Section: Do Increases In Uptake Mirror Gains In Education?mentioning

confidence: 99%

Biosimilar Uptake: The Importance of Healthcare Provider Education

Oskouei

Kusmierczyk

2021

Pharm Med

View full text Add to dashboard Cite

show abstract

“…12,13 The most recent American College of Rheumatology guidelines now favour moving to a different drug class rather than sequential TNF inhibition. 14 All the TNF inhibitors have comparable efficacy, with the choice of agent generally being dependent on patient preference for route of administration and frequency of treatment.…”

Section: Tnf Inhibitorsmentioning

confidence: 99%

“…In patients with a previous history of lymphoproliferative malignancy rituximab remains a favourable option as it is also used in the treatment of lymphoma. 14…”

Section: Cd-20 Depleting Antibodiesmentioning

confidence: 99%

Biological Therapies for Rheumatoid Arthritis: An Overview for the Clinician

Findeisen¹,

Sewell²,

Östör³

2021

BTT

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a disease characterised by inflammation of synovial joints and poses a substantial healthcare burden on both the individual and society. One of the most significant shifts in the RA therapeutic landscape has occurred with the introduction of biological disease modifying anti-rheumatic drugs (bDMARDs). There are five classes of bDMARDs currently available, each with a different molecular target and subtle differences in their efficacy and safety profile. This review also describes the “real-world” use of bDMARDs and how they fit into the overall RA treatment guidelines.

show abstract

“…In the 2021 American College of Rheumatology (ACR) RA therapy guideline, it is stated that anti-TNFs can be used preferably in combination with conventional Disease-Modifying Anti-Rheumatic drugs (cDMARDs) such as methotrexate, or alone [10]. Although many studies report that the anti-TNF agents have similar effects, contradictions remain.…”

Section: Introductionmentioning

confidence: 99%

Which anti-TNF is most effective for my patient? Which one should I choose?

Pamukçu¹,

Baykara²

2021

Journal of Surgery and Medicine

View full text Add to dashboard Cite

Background/Aim: Multicenter controlled studies were conducted on the effect of anti-Tumor Necrosis Factor (TNF) agents in rheumatoid arthritis (RA) and varying effectiveness rates were reported. These agents have different advantages over each other. We aimed to compare the disease activation parameters in patients with RA at the beginning and the 52 nd week of therapy in patients who were followed up in our center and started on anti-TNF (etanercept, adalimumab, and golimumab), and examine the effects of the drugs that are used by comparing them with each other. Methods: This retrospective cohort study included 187 patients with RA who were started on anti-TNF therapy because the disease activity could not be controlled by the concomitant use of at least three different conventional Disease-Modifying Anti-Rheumatic drugs, and whose adequate response to anti-TNF were observed at the 12th-week follow-up. RA disease activity was measured using the 28-joint Disease Activity Score incorporating erythrocyte sedimentation rate (DAS-28 ESR) and the patients were evaluated by a Health Assessment Questionnaire (HAQ). For each drug group, disease activation and laboratory parameters were compared before treatment initiation and at 52 weeks of treatment. These values were then compared between the drug groups. Results: The mean age of 187 patients included in the study was 52.70 (10.17) years, 119 (63.6%) were female and 68 (36.4%) were male. Of the patients, 63 (33.7%) were using adalimumab, 62 (33.2%) were using etanercept and 62 (33.2%) were using golimumab. In all patients, there was a significant improvement in all parameters except mean corpuscular hemoglobin, gamma-glutamyl transferase, and creatinine. There were significant changes in hemoglobin, leukocyte and platelet count, erythrocyte sedimentation rate, C reactive protein, neutrophil count, serum albumin, DAS-28 ESR, and HAQ levels in all three groups (P<0.05). Conclusion: There were no differences in efficacy between adalimumab, etanercept and golimumab therapies, which were planned considering the comorbidities and drug preferences of the patients. In addition to controlled studies, real-life data to be reported by rheumatology centers will help us obtain more accurate information about the therapy results of anti-TNF agents.

show abstract

2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

Cited by 551 publications

References 70 publications

Biosimilar Uptake: The Importance of Healthcare Provider Education

Biosimilar Uptake: The Importance of Healthcare Provider Education

Biological Therapies for Rheumatoid Arthritis: An Overview for the Clinician

Which anti-TNF is most effective for my patient? Which one should I choose?

Contact Info

Product

Resources

About